The HALLMOUNT Score: Development of a Novel Multidimensional Prognostic Model for Solid Tumors, with Initial Clinical...

Area of Science:

• Neuro-oncology
• Biomarker Discovery
• Clinical Prognostics

Background:

• Grade 4 adult-type diffuse gliomas are aggressive CNS malignancies with limited prognostic tools.
• Molecular classification is key, but integrating systemic host response is crucial for better prediction.

Purpose of the Study:

• To introduce and validate the HALLMOUNT score, a multidimensional prognostic index for grade 4 adult-type diffuse gliomas.
• To assess the score's ability to integrate tumor biology and host response for improved prognostication.

Main Methods:

• Retrospective analysis of 227 patients with grade 4 adult-type diffuse glioma.
• The HALLMOUNT score incorporates nine pretreatment variables: hemoglobin, albumin, LDH, lymphocyte, monocyte, ECOG, uric acid, neutrophil, and thrombocyte counts.
• ROC analyses and Cox regression models were used to evaluate prognostic performance for OS and PFS.

Main Results:

• High HALLMOUNT scores (≥2.5) correlated with older age, comorbidities, poor ECOG status, IDH-wild phenotype, lower resection rates, and reduced treatment response.
• The HALLMOUNT score demonstrated predictive accuracy comparable to existing markers (AUC = 0.650).
• High scores independently predicted significantly inferior overall survival (OS) and progression-free survival (PFS).

Conclusions:

• The HALLMOUNT score is a simple, cost-effective biomarker reflecting tumor aggressiveness and host vulnerability in diffuse gliomas.
• It allows for refined risk stratification and supports individualized therapeutic planning.
• Prospective validation in diverse cohorts is warranted.